Product Update
Potential Value of Cyclurad™
Ingredient Identified for
Treating Depression
GeneSight® Improved to Include More Options for Making
Neuropsychiatric Disorder Medication Decisions
Assurex Health, Inc., announced a significant enhancement to its GeneSight®
Psychotropic test, giving health care providers an expanded range of options to
help make medication decisions for patients with depression, anxiety, bipolar disorder, posttraumatic stress disorder, schizophrenia, and other behavioral health
conditions.
With the addition of two new
drug classes, 17 U.S. Food and Drug
Administration–approved
medications, and four clinically validated
genes, GeneSight Psychotropic now
covers 97% of prescriptions written to
treat depression, anxiety, bipolar disorder, and schizophrenia.
GeneSight Psychotropic is a
comprehensive neuropsychiatric pharmacogenomics test that (a) uses combinatorial pharmacogenomics; (b) has the most clinical data supporting its
clinical validity and use; (c) includes more relevant genes than its competition; and (d) analyzes the most relevant medications and drug classes that
cover neuropsychiatric disorders.
© 2016 Shutterstock.com
The
active
ingredient
of
Cyclurad™ by NeuroRx, Inc., has
been identified as potentially promising in the treatment of depression,
according to a report in the American
Journal of Psychiatry.
The
American
Psychiatric
Association Task Force identified
D-cycloserine as one of only two
molecules currently on the research
horizon that shows promise for
repeated administration in the treatment of depression via modulation of
the NMDA receptor. D-cycloserine is
one of the two active ingredients of
Cyclurad.
© 2016 Shutterstock.com
Source. “Assurex Health Enhances Clinically Proven Genetic Test to Help Healthcare Providers Choose Psychiatric Medications for Patients.” (2015, December 1). Retrieved December 2, 2015, http://prn.to/1NsgASS.
The task force conducted an extensive review of the scientific literature.
The report highlights the short-term
nature of the ketamine response and
18
the documented incidence of hallucinations and other psychomimetic
side effects as limiting the use of ketamine in isolation for the treatment
of depression. The findings continued
with a comprehensive analysis of all
currently investigational molecules
that act on the NMDA receptor and
may be valuable in the treatment of
depression.
The report is the second independent, peer-reviewed confirmation of
the potential value of D-cycloserine
in extending the effect of ketamine
in the treatment of acute depression.
Source. “American Psychiatric Association Task
Force Report Identifies Potential Value of NeuroRx Active
Ingredient for Treatment of Depression.” (2015, October
21). Retrieved December 2, 2015, from http://prn.
to/1LrwCKu.
doi:10.3928/02793695-20160119-02
Copyright © SLACK Incorporated